0.36
+0.0025(+0.69%)
Currency In USD
Address
170 Harbor Way
South San Francisco, CA 94080
United States of America
Phone
650 550 3500
Website
Sector
Healthcare
Industry
Biotechnology
Employees
105
First IPO Date
December 11, 1981
| Name | Title | Pay | Year Born |
| Mr. Steven Lo | President, Chief Executive Officer & Director | 879,327 | 1967 |
| Dr. Sean N. Tucker Ph.D. | Senior Vice President & Chief Scientific Officer | 622,439 | 1968 |
| Dr. James F. Cummings M.D. | Chief Medical Officer | 679,943 | 1967 |
| Mr. Phillip Eric Lee | Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer | 0 | 1988 |
| Dr. Raymond D. Stapleton Jr., Ph.D. | Chief Technology Officer | 0 | 1972 |
| Mr. Edward B. Berg | Senior Vice President & General Counsel | 0 | 1965 |
| Ms. Laurie Hastings | Senior Vice President of Human Resources | 0 | N/A |
| Ms. Shaily Jaini Garg | Senior Vice President of Clinical Development & Project Management | 0 | N/A |
| Dr. Rajesh Kapoor Ph.D. | Senior Vice President of Quality | 0 | N/A |
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company is headquartered in South San Francisco, California.